Clinical trials: Prostate Cancer Diagnosis
Prostatic Neoplasms
A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of a vaccine-based immunotherapy regimen for patients with prostate cancer.
- Trial name
- NCT02616185
- Testing
- PF-06755992, PF-06755990, TDS-IM Electroporation Device
- Where
- 19 sites in United States
- Volunteers
- 91 people
- Sponsor
- Pfizer
Prostate Cancer
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00589420
- Testing
- docetaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well metformin hydrochloride works compared to placebo in treating patients with prostate cancer undergoing surgery. Metformin hydrochloride may make some enzymes active.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01433913
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate
Enzalutamide in Patients With High-risk Prostate Cancer
The purpose of this study is to see how long it takes for prostate cancer to come back in patients who have had surgery to remove their prostate gland (radical prostatectomy), while being treated with enzalutamide (formerly known…
- Trial name
- NCT01927627
- Testing
- enzalutamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Prostatic Neoplasms
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
- Trial name
- READY (NCT00744497)
- Testing
- Dasatinib, Docetaxel, Prednisone
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 1,930 people
- Sponsor
- Bristol-Myers Squibb
Prostate Cancer Metastatic
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer.
- Trial name
- Prospect (NCT01322490)
- Testing
- PROSTVAC-V, PROSTVAC-F, GM-CSF
- Where
- 220 sites in United States, Australia and 14 more
- Volunteers
- 1,297 people
- Sponsor
- Bavarian Nordic
Metastatic Cancer, Prostate Cancer
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
RATIONALE: Diagnostic procedures, such as radionuclide imaging using calcium-41 (41Ca) chloride aqueous solution, may help predict progressive disease in patients with prostate cancer and bone metastasis.
- Trial name
- UCDCC#217 (NCT00918645)
- Testing
- 41 Ca
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, Davis
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Prostatic Neoplasms
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named…
- Trial name
- NCT02443571
- Testing
- Fluciclovine (18F)
- Where
- 4 sites in United States, Italy and 1 more
- Volunteers
- 714 people
- Sponsor
- Blue Earth Diagnostics
Prostatic Neoplasms, Genital Neoplasms, Male
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
This prospective trial aims to determine if enhanced prostate imaging using two novel imaging technologies (high resolution DWI and 18F-PSMA PET-MRI) will detect prostate cancers not seen on standard multiparametric prostate MRI…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
- Trial name
- NCT04461509
- Testing
- 18F-PSMA
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Alessandro D'Agnolo
Prostatic Neoplasms, Castration-Resistant
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate…
- Trial name
- NCT02204072
- Testing
- BI 836845, Enzalutamide
- Where
- 27 sites in United States, Hong Kong and 6 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Colon Cancer, Lung Cancer
Effectiveness of Electronic Health Record-Based Interventions for Improving Follow-Up in Primary Care
Diagnostic delays in ambulatory care are often due to breakdowns of related care processes. Electronic systems can improve follow-up and reduce delays by detecting missed appointments or incomplete procedures so that patients are…
- Conditions
- Colon Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT01346839
- Testing
- Contact Intervention
- Where
- 2 sites in United States
- Volunteers
- 1,256 people
- Sponsor
- Baylor College of Medicine
Prostate Cancer
AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
This study is to obtain acute dose safety and pharmacokinetics/pharmacodynamics (PK/PD) data in a dose-response trial in prostate cancer patients.
- Trial name
- NCT05375539
- Testing
- AGN-Cogni.Q
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Milton S. Hershey Medical Center
Hormone Sensitive Prostate Cancer, Prostate Cancer
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- Trial name
- NCT02319837
- Testing
- Enzalutamide, Leuprolide Open Label
- Where
- 255 sites in United States, Australia and 15 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Prostate Cancer
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Pilot Immunotherapy Study of Combination Prostate Specific Membrane Antigen (PSMA) and T-cell receptor γ alternate reading frame protein (TARP) Peptide With Poly IC-LC Adjuvant in Human Leukocyte Antigens (HLA)-A2 (+) Patients…
- Trial name
- NCT00694551
- Testing
- Peptide Vaccine, Poly IC-LC
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
Evaluation of Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.
The Calypso® System (Varian Medical Systems, Inc., Palo Alto, CA) is a recent technology using electromagnetic transponders implanted within the prostate.
- Trial name
- RCMIGI (NCT03254420)
- Testing
- Calypso beacon implant, moderate hypofractionation Radiotherapy
- Where
- France
- Volunteers
- 74 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Prostate Cancer
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
- Trial name
- NCT00203424
- Testing
- Erlotinib + Bevacizumab
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Translational Oncology Research International
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer
This phase II trial studies the how well apalutamide with or without stereotactic body radiation therapy work in treating participants with castration-resistant prostate cancer.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
- Trial name
- PILLAR (NCT03503344)
- Testing
- Apalutamide, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.